Development of novel oral formulation to treat systemic fungal infections

March 23, 2020

The Wasan Laboratory in the Faculty of Pharmaceutical Sciences at the University of British Columbia in partnership with iCo Therapeutics Inc. (Vancouver BC, Canada) have developed a novel oral formulation of Amphotericin B to treat systemic fungal and parasitic infections. Amphotericin B is a polyene macrolide antibiotic used in the treatment of blood borne fungal infections such as candidiasis and aspergillosis and parasitic infections such as visceral leishmaniasis. However, its effectiveness has been limited by dose-dependent nephrotoxicity, drug formulation costs, patient medication adherence and parenteral administration, which is not always accessible, costly and has additional toxicities associated with this route of administration. The rationale for the development of an oral amphotericin B formulation was that it could help overcome the aforementioned limitations by being less nephrotoxic, cost-effective, improve patient drug adherance and eliminate parenteral administration-associated costs and toxicities. The Wasan lab conducted in vitro cell culture studies and various animal studies to identify a lead formulation for clinical development. This lead formulation has recently successfully completed phase 1b human clinical trials and will start on phase 2 human clinical trials in comparing Oral Amp B to fluconazole in a head-to-head study in vulvovaginal candidiasis later in 2020. As noted in iCo Therapeutics recent press release Dr. Kishor Wasan, co-inventor of the Oral Amp B technology and Amphotericin B expert, noted that "traditionally Amphotericin B has been limited by an intravenous (IV) route of administration and limited therapeutic window. The impressive safety profile of Oral Amp B addresses one of two such limitations. I look forward to the initiation of a Phase 2 study in the near future which will investigate the efficacy of an oral version of Amphotericin B versus current standard of care, potentially addressing the second limitation of the current generic IV version of the drug."
-end-
For more information, please visit: http://www.eurekaselect.com/180111/article

Bentham Science Publishers

Related Pharmaceutical Sciences Articles from Brightsurf:

GARDP partners with Japanese pharmaceutical in pursuit of new antibiotics
The Global Antibiotic Research and Development Partnership (GARDP) has today announced an agreement with Daiichi Sankyo for GARDP to access and screen the Daiichi Sankyo chemical library.

The integrated catalysts can simplify pharmaceutical manufacturing
Prof. In Su Lee and his research team from POSTECH developed catalytic platforms based on metal organic frameworks.

Study: Pharmaceutical companies marketing stimulants to physicians
Results of a new study show that a large number of physicians in the US may have received marketing payments from pharmaceutical companies that produce stimulant medications.

3D printing with applications in the pharmaceutical industry
This achievement will have applications in the pharmaceutical industry, such as in the preparation of biocompatible biosensors based in gold, which have already been shown to be effective in the detection of carcinogenic cells and tumour biomarkers.

Turning wood into pharmaceutical ingredients 
Production of hazardous waste during drug manufacturing is a serious concern for the pharmaceutical industry.

New pharmaceutical target reverses osteoporosis in mice
Biomedical engineers at Duke University have discovered that an adenosine receptor called A2B can be pharmaceutically activated to reverse bone degradation caused by osteoporosis in mouse models of the disease.

Active pharmaceutical ingredients can persist in the environment
A study finds trace levels of medicines in drinking water from private wells.

Drug development stakeholders call for improved pharmaceutical testing
Published in Drug Discovery Today, 'Advancing Nonclinical Innovation and Safety in Pharmaceutical Testing' identifies the necessary steps that will lead to safer and more effective medicines, guided by a greater focus on human-based in vitro and in silico methods, which allow scientists to observe human cells, tissues, and biological processes, and their interaction with potential medications.

A step ahead in pharmaceutical research
Researchers of the University of W├╝rzburg have developed a method that makes it possible to measure the activation of receptors in a very short time.

Are pharmaceutical marketing payments to physicians for opioids associated with prescribing?
Pharmaceutical industry marketing of opioid products to physicians through nonresearch payments, which can include speaking fees and meals, was associated with greater opioid prescribing.

Read More: Pharmaceutical Sciences News and Pharmaceutical Sciences Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.